A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
About the study
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Completion of the study treatment period of the originating parent study (INCB 54707-301 or INCB 54707-302).
- Agreement to use contraception.
- Willing and able to comply with the study protocol and procedures.
* Further inclusion criteria apply.
EXCLUSION CRITERIA
Exclusion Criteria:
- Participation in the extension study could expose the participant to an undue safety risk.
- Women who are pregnant (or who are considering pregnancy) or breastfeeding.
* Further exclusion criteria apply.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Hidradenitis Suppurativa (HS)
Age
18+
Phase
PHASE3
Participants Needed
960
Est. Completion Date
Dec 26, 2026
Treatment Type
INTERVENTIONAL
Sponsor
Incyte Corporation
ClinicalTrials.gov NCT Identifier
NCT06212999
Study Number
INCB 54707-312
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?